(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
07 April 2022 (07.04.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/072517 A1

(51) International Patent Classification:
A61K 31/34 (2006.01) *A61K 31/537* (2006.01)
A61K 31/39 (2006.01) *A61P 29/00* (2006.01)
A61K 31/40 (2006.01)

(21) International Application Number:
PCT/US2021/052679

(22) International Filing Date:
29 September 2021 (29.09.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/085,849 30 September 2020 (30.09.2020) US

(71) Applicant: **METACRINE, INC.** [US/US]; 3985 Sorrento Valley Blvd., Suite C, San Diego, California 92121 (US).

(72) Inventors: **HUDSON, Andrew R.**; 3985 Sorrento Valley Blvd., Suite C, San Diego, California 92121 (US). **GOVEK, Steven P.**; 3985 Sorrento Valley Blvd., Suite C, San Diego, California 92121 (US). **NAGASAWA, Johnny Y.**; 3985 Sorrento Valley Blvd., Suite C, San Diego, California 92121 (US). **BOTROUS, Iriny**; 3985 Sorrento Valley Blvd., Suite C, San Diego, California 92121 (US). **SMITH, Nicholas D.**; 3985 Sorrento Valley Blvd., Suite C, San Diego, California 92121 (US). **FASANYA, Karensa L.**; 3985 Sorrento Valley Blvd., Suite C, San Diego, California 92121 (US).

(74) Agent: **MALECHA, James**; Wilson Sonsini, 650 Page Mill Road, Palo Alto, California 94304 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

WO 2022/072517 A1

(54) Title: HSD17B13 INHIBITORS AND USES THEREOF

(57) Abstract: Described herein are compounds that are HSD17B13 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with HSD17B13 activity.